Long-Term Safety Follow-Up for Seattle Children's Gene Therapy Products Initiated
Seattle Children's Hospital is conducting a long-term follow-up study to assess the safety of its gene therapy products over a period of up to 15 years.
Asset / Drug
Drug and asset intelligence for Long-Term with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Gene Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.